Antimicrobial atresia with tauryl amine derivatives and carboxyl acid and/or its salt
A technology of taurolidine and citric acid, which is applied in the field of flushing and coating catheter compositions, and can solve the problems that taurolidine has no effective therapeutic effect and the like
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0104] A 0.5% solution of taurolidine in Ringer's-lactate solution (Thomae, Biberach, Germany) was introduced into four polyethylene bottles of 30 ml volume. Fill volumes are 5, 10 and 15ml. One bottle was filled with a solution of 5 ml taurolidine and 2 ml ACD-A (Fresenius, Bad Homburg, Germany). ACD-A solution is used for whole blood preservation and contains per liter: 22.0 g sodium citrate dihydrate, 7.3 g citric acid and 34.5 g dextrose monohydrate.
[0105] Blood was collected from sows in the slaughterhouse, directly from the slaughter wound into containers, which were then filled to the 30ml level. Cap the container and agitate gently to mix the blood with the solution. The container was inspected after 30 minutes. Blood clots in containers containing only taurolidine, but not clots in containers containing a mixture of taurolidine and ACD-A. Therefore, it was concluded that the combined use of sodium citrate and citrate anticoagulants with taurolidine provided con...
Embodiment 2
[0107] A subcutaneously implantable titanium channel system of the type described in US Patent Application Serial No. 08 / 485,498 was used in this example. It is connected to two 12French siliconized rubber catheters that end in the right atrium. The valves of the channel are opened by two special needles so that the blood flow is about 300ml / min.
[0108] With the consent of the patients, channels were implanted by experienced nephrologists in 10 female patients and 6 male patients with an average age of 68±9. Nine of the sixteen patients were diabetic. The entry criteria for patients studied was vessel exhaustion resulting in no hemodialysis site in the arm. Eight of sixteen cases had severe congestive heart failure, and all patients had high comorbidity. Nine patients started hemodialysis immediately after implantation, the others underwent long-term hemodialysis and switched from catheter to channel system (four patients exchanged by guidewire). No peripheral surgical c...
Embodiment 4
[0118] In this example, which describes the experiments of Example 2 in more detail, the subcutaneously implantable peptide channel system described in Example 2 was used.
[0119] In a prospective multicenter pilot trial starting June 1998, 31 channels were implanted in 19 female patients and 12 male patients (mean age 66, minimum 30, maximum 81). In addition to accepting new devices, the aim of the study was to avoid infections supported by a completely non-toxic mixture (heparin-free occlusive solution containing taurolidine as an anti-infective substance and citric acid / sodium citrate to inhibit coagulation), This mixture has excellent efficacy against any microorganisms, even multi-drug resistant ones.
[0120] Among the 10 participating centers, there have been no channel losses since the start of the study (3847 days of engraftment). Despite a high co-morbidity rate, only two patients experienced a bloodstream-related infection (S. aureus). The overall observed infect...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More